A new predictor of the efficacy of immunotherapy for non-small cell lung cancer—lung immune prognostic index (LIPI)

Abstract

Zhang Aixia, Sun Yahong. A new predictor of the efficacy of immunotherapy for non-small cell lung cancer—lung immune prognostic index (LIPI)[J]. Journal of International Oncology, 2020, 47(5): 301-303.

References20

[1]	Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade[J]. Science, 2018,359(6382):1350-1355. DOI: 10.1126/science.aar4060. doi:10.1126/science.aar4060pmid:29567705
[2]	Park YJ, Kuen DS, Chung Y. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance[J]. Exp Mol Med, 2018,50(8):109. DOI: 10.1038/s12276-018-0130-1. doi:10.1038/s12276-018-0130-1pmid:30135516
[3]	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015,373(17):1627-1639. DOI: 10.1056/NEJMoa1507643. doi:10.1056/NEJMoa1507643pmid:26412456
[4]	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015,373(2):123-135. DOI: 10.1056/NEJMoa1504627. doi:10.1056/NEJMoa1504627pmid:26028407
[5]	Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial[J]. Lancet, 2016,387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. doi:10.1016/S0140-6736(15)01281-7pmid:26712084
[6]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016,375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. doi:10.1056/NEJMoa1606774pmid:27718847
[7]	Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicenter randomised controlled trial[J]. Lancet, 2017,389(10066):255-265. DOI: 10.1016/S0140-6736(16)32517-X. doi:10.1016/S0140-6736(16)32517-Xpmid:27979383
[8]	Hopkins AM, Rowland A, Kichenadasse G, et al. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers[J]. Br J Cancer, 2017,117(7):913-920. DOI: 10.1038/bjc.2017.274. doi:10.1038/bjc.2017.274pmid:28950287
[9]	Prelaj A, Tay R, Ferrara R, et al. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer[J]. Eur J Cancer, 2019,106:144-159. DOI: 10.1016/j.ejca.2018.11.002. doi:10.1016/j.ejca.2018.11.002pmid:30528799
[10]	Peters S, Gettinger S, Johnson ML, et al. Phase Ⅱ trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)[J]. J Clin Oncol, 2017,35(24):2781-2789. DOI: 10.1200/JCO.2016.71.9476. doi:10.1200/JCO.2016.71.9476pmid:28609226
[11]	Spigel DR, Chaft JE, Gettinger S, et al. FIR: efficacy, safety, and biomarker analysis of a phase Ⅱ open-label study of atezolizumab in PD-L1-selected patients with NSCLC[J]. J Thorac Oncol, 2018,13(11):1733-1742. DOI: 10.1016/j.jtho.2018.05.004. doi:10.1016/j.jtho.2018.05.004pmid:29775807
[12]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011,144(5):646-674. DOI: 10.1016/j.cell.2011.02.013. doi:10.1016/j.cell.2011.02.013
[13]	Zhu L, Li X, Shen Y, et al. A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer[J]. Onco Targets Ther, 2016,9:4879-4886. DOI: 10.2147/OTT.S107279. doi:10.2147/OTT.S107279pmid:27540301
[14]	Laird BJ, Fallon M, Hjermstad MJ, et al. Qualityof life in patients with advanced cancer: differential association with performance status and systemic inflammatory response[J]. J Clin Oncol, 2016,34(23):2769-2775. DOI: 10.1200/JCO.2015.65.7742. doi:10.1200/JCO.2015.65.7742pmid:27354484
[15]	McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer[J]. Cancer Treat Rev, 2013,39(5):534-540. DOI: 10.1016/j.ctrv.2012.08.003. doi:10.1016/j.ctrv.2012.08.003pmid:22995477
[16]	Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer[J]. JAMA Oncol, 2018,4(3):351-357. DOI: 10.1001/jamaoncol.2017.4771. doi:10.1001/jamaoncol.2017.4771pmid:29327044
[17]	Sorich MJ, Rowland A, Karapetis CS, et al. Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials[J]. J Thorac Oncol, 2019,14(8):1440-1446. DOI: 10.1016/j.jtho.2019.04.006. doi:10.1016/j.jtho.2019.04.006pmid:30999110
[18]	Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016,387(10030):1837-1846. DOI: 10.1016/S0140-6736(16)00587-0. doi:10.1016/S0140-6736(16)00587-0pmid:26970723
[19]	Kazandjian D, Gong Y, Keegan P, et al. Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small-cell lung cancer[J]. JAMA Oncol, 2019,5(10):1481-1485. DOI: 10.1001/jamaoncol.2019.1747. doi:10.1001/jamaoncol.2019.1747
[20]	Kim YJ, Kim CH, Lee SH, et al. Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced NSCLC treated with immune checkpoint inhibitor[J]. J Thorac Oncol, 2019,14(9):1608-1618. DOI: 10.1016/j.jtho.2019.05.033. doi:10.1016/j.jtho.2019.05.033pmid:31195179

A new predictor of the efficacy of immunotherapy for non-small cell lung cancer—lung immune prognostic index (LIPI)

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References20

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[11]	Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165.
[12]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[13]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[14]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[15]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.